Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 27, 2026

Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?

Here is how Amneal Pharmaceuticals (AMRX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

Zacks Investment Research • Oct 27, 2026

Implied Volatility Surging for Amneal Pharmaceuticals Stock Options

Investors need to pay close attention to AMRX stock based on the movements in the options market lately.

Zacks Investment Research • Oct 27, 2026

Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Oct 26, 2026

Amneal to Report Third Quarter 2026 Results on November 3, 2026

BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.

GlobeNewsWire • Oct 8, 2026

Amneal Announces FDA Approval and Launch of Lanreotide Injection

- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production

GlobeNewsWire • Sep 18, 2026

Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?

Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research • Sep 17, 2026

5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low

COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.

Zacks Investment Research • Aug 27, 2026

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Zacks Investment Research • Aug 20, 2026

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)---- $AMRX #AMRX--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders.The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional informat.

Business Wire • Aug 19, 2026